Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Heinz A. Horst"'
Autor:
Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent L. Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli
Publikováno v:
Cancers, Vol 13, Iss 22, p 5607 (2021)
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph
Externí odkaz:
https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec
Autor:
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Andreas Viardot, Heinz A. Horst, Svenja Neumann, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Dorothea Wessiepe, Max S. Topp, Ralf Bargou
Publikováno v:
Haematologica, Vol 102, Iss 4 (2017)
Externí odkaz:
https://doaj.org/article/01ce29e1989f4f4d84b31b21bf6b1ade
Autor:
Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, Jürgen Krauter, Daniela Weber, Margit Moessner, Claus-Henning Köhne, Heinz A. Horst, Ingo G.H. Schmidt-Wolf, Mathias Rummel, Katharina Götze, Elisabeth Koller, Andreas L. Petzer, Hans Salwender, Walter Fiedler, Heinz Kirchen, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel C. Matzdorff, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m2 intravenously on day 1), all-trans retinoic acid (45 mg/m2 orally on day
Externí odkaz:
https://doaj.org/article/e94817aacaec41859b402566beb720a7
Autor:
Nicolas Boissel, Nicola Gökbuget, Anthony S. Stein, Max S. Topp, Hagop M. Kantarjian, Yuqi Chen, Gerhard Zugmaier, Heinz-August Horst, Monika Brüggemann, Giovanni Martinelli
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2601-2610 (2021)
Cancer Medicine
Cancer Medicine
Background Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). Aims To assess the efficacy and safety of blinatumoma
Autor:
Thomas Schroeder, Hartmut Döhner, Heinz A. Horst, Arnold Ganser, Nadezda Basara, Julia Krzykalla, Karin Mayer, Axel Benner, Uwe M. Martens, Martin Bentz, Michael Lübbert, Peter Paschka, Thomas Kindler, Richard F. Schlenk, Michael Girschikofsky, Michael Heuser, Gerald Wulf, Elisabeth Koller, Katharina Götze, Richard Greil, Bernd Hertenstein, Felicitas Thol, Jürgen Krauter, Daniela Weber, David Nachbaur, Claudia Leis, Jan Schleicher, Walter Fiedler, Maisun Abu Samra, Konstanze Döhner, Silke Kapp-Schwoerer, Mohammed Wattad, Verena I. Gaidzik
Publikováno v:
Journal of Clinical Oncology
PURPOSE High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive indu
Autor:
Monika Brüggemann, Brent L. Wood, Yi Zeng, Heinz A. Horst, Gerhard Zugmaier, Hagop M. Kantarjian, Giovanni Martinelli
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5607, p 5607 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5607, p 5607 (2021)
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph
Autor:
Philippe Rousselot, Veronica Teleanu, Kimmo Porkka, Christian Recher, Achilles Anagnostopoulos, Oliver G. Ottmann, Miguel A. Sanz, Daniel J. DeAngelo, Mikkael A. Sekeres, Felicitas Thol, Hartmut Döhner, Kensuke Usuki, Konstanze Döhner, Dries Deeren, Miaomiao Ge, Stefano D'Ardia, Olga Salamero, Irwindeep Sandhu, Chul Won Jung, Tillmann Taube, Je-Hwan Lee, Tomoki Naoe, Koen Theunissen, Jordi Esteve, Heinz-August Horst, Judit Demeter, Walter Fiedler, Valerie Belsack, Argiris Symeonidis, Hee-Je Kim
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e617 (2021)
HemaSphere
Scientia
HemaSphere
Scientia
Terapia de inducción estándar; Volasertib adyuvante; Leucemia mieloide aguda Standard Induction Therapy; Adjunctive Volasertib; Acute Myeloid Leukemia Teràpia d'inducció estàndard; Volasertib adjuvant; Leucèmia mieloide aguda In this phase 3 tr
Autor:
Uwe M. Martens, Jörg Westermann, Peter Paschka, Helmut R. Salih, Richard Greil, Thomas Südhoff, Konstanze Döhner, Julia Krzykalla, Thomas Kindler, Bernd Hertenstein, Verena I. Gaidzik, Wolfgang Herr, Michael Girschikofsky, Alexander Burchardt, Thomas Schroeder, Gerhard Held, Michael Heuser, Katharina Götze, Gerald Wulf, Roland Schroers, Daniela Weber, Richard F. Schlenk, Elisabeth Lange, Doris Kraemer, Hartmut Döhner, Axel Benner, Michael Lübbert, Mark Ringhoffer, Arnold Ganser, Felicitas Thol, Hans-Günter Derigs, Martin Grießhammer, Heinz-August Horst, Lore Marretta, Jürgen Krauter, Walter Fiedler, Hans Salwender, Dominik Wolf
Publikováno v:
Blood. 133:840-851
Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibit
Autor:
Laura Hamacher, Stefan Esser, Clara Lehmann, Christian Kollan, Annette Haberl, Christoph Boesecke, Philipp Schommers, Melanie Stecher, Carlos Fritzsche, Carolynne Schwarze-Zander, Hans-Jürgen Stellbrink, Barbara Gunsenheimer-Bartmeyer, Jörg Janne Vehreschild, Gerd Fätkenheuer, Björn Jensen, Christoph Stephan, Olaf Degen, Heinz-August Horst, Christian Hoffmann, Daniel Schmidt, Matthias Stoll, Dirk Schürmann, Johannes R. Bogner, Martin Platten, Frieder Kuhlendahl, Jan-Christian Wasmuth
Publikováno v:
Infection
Combination antiretroviral therapy (cART) has markedly increased survival and quality of life in people living with HIV. With the advent of new treatment options, including single-tablet regimens, durability and efficacy of first-line cART regimens a
Autor:
Thomas Schroeder, Arnold Ganser, Axel Benner, Nikolaus Jahn, Walter Fiedler, Hartmut Döhner, Anika Schrade, Martin Bentz, Julia Herzig, Karin Mayer, Lena Kubanek, Verena I. Gaidzik, Thomas Kindler, Jan Schleicher, Frank G. Rücker, Frauke Theis, Peter Paschka, Julia Krzykalla, Gudrun Göhring, Gerald Wulf, Jürgen Krauter, Elisabeth Koller, Michael Heuser, Jan Krönke, Lars Bullinger, Andrea Corbacioglu, Ekaterina Panina, Daniela Weber, Maria-Veronica Teleanu, Heinz A. Horst, Silke Kapp-Schwoerer, Felicitas Thol, Mohammed Wattad, Richard F. Schlenk, Michael Lübbert, Katharina Götze, Konstanze Döhner
Publikováno v:
Blood. 136(26)
Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials. We det